demonstrated that in breast cancer cells, HBXIP increased METTL3 expression by interfering with let-7g, a miRNA binding to the 3′UTR of METTL3, which subsequently interfered with METTL3 expression (82). The gene discussed is METTL3; the disease is breast carcinoma.